Blog
Operating revenue has grown for eight consecutive years! In 2024, Qizheng Tibetan Medicine’s operating revenue increased by 14.32%, and the company plans to distribute a cash dividend of 3.8 yuan for every 10 shares held.
Release time:
2025-04-26 13:12
According to a report by the Shanghai Securities Journal, Qizheng Tibetan Medicine disclosed its 2024 annual results on the evening of April 24. During the reporting period, the company achieved another record high in operating performance, with revenue growing steadily for eight consecutive years. The company’s full-year revenue reached RMB 2.338 billion, up 14.32% year-on-year. Net profit attributable to shareholders of the listed company came in at RMB 582 million, representing a slight increase over the previous year. Net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, reached RMB 426 million, up 15.09% year-on-year. The company plans to distribute a cash dividend of RMB 3.8 per 10 shares to all shareholders (including tax).
2024 is a pivotal year for Qizheng Tibetan Medicine’s “Dual-Drive, Dual-Leading, Dual-Foundation” strategy. The company has further enhanced its industry standing, ranking 28th on the “2023 Top 100 Chinese Traditional Chinese Medicine Enterprises” list compiled by MeneNet—up one spot from the previous year. It was also listed among the “Top 100 in Comprehensive Competitiveness of the Pharmaceutical Industry 2024” and the “Top 50 in Comprehensive Competitiveness of the Chinese Patent Medicine Industry 2024” by the China Pharmaceutical Industry Association (CPIA), with a brand value of 3.15 billion yuan.
During the reporting period, the company’s core product in the musculoskeletal system—the pain-relief plaster—continued to consolidate its market share. Bai Mai Ointment and Ruyi Zhenbao Tablets have emerged as new growth drivers in the musculoskeletal pain relief segment. In the respiratory field, sales of Shiwai Longdanhua have continued to rise, further enhancing the product’s brand influence. In the digestive sector, Liuwei Nengxiao Tablets achieved rapid growth and have become a key product within the “Shan Wei” family. In the gynecological area, Honghua Ruyi Pills also recorded relatively fast growth. Through the synergistic efforts of academic marketing, brand marketing, digital marketing, and channel expansion, the company has enhanced the coverage of its products in both retail and healthcare markets, resulting in a substantial year-on-year increase in sales.
In 2024, the company’s R&D investment reached 104.7 million yuan, representing a year-on-year increase of 5.35%; the number of R&D personnel stood at 318, up 8.16% from the previous year. In the field of new drug research, Bai Mai Ointment has become the first traditional Chinese medicine product to be exempted from Phase II clinical trials and proceed directly to Phase III clinical trials.
For the 16th consecutive year, Qizheng Tibetan Medicine has released its Environmental, Social, and Governance (ESG) Report, which reveals that the company has established a green and sustainable supply chain to ensure the quality and stability of medicinal materials. As of the end of the reporting period, the company has conducted cultivation technology research on a total of 58 plant species, with a combined area of various bases—primarily focused on wild cultivation and conservation—reaching 502,450 mu.
The company also disclosed its first-quarter report for 2025. In the first quarter of this year, the company achieved operating revenue of 403 million yuan, representing a year-on-year increase of 10.39%. Net profit attributable to shareholders of the listed company reached 75.6798 million yuan, and net profit attributable to shareholders of the listed company excluding non-recurring gains and losses amounted to 65.1835 million yuan, up 16.34% year-on-year.
Reporting media: Shanghai Securities Journal·China Securities Network
Report link: https://www.cnstock.com/commonDetail/412192
Recommended News
2026-05-25
Copyright Qizheng Tibetan Medicine Co., Ltd. All rights reserved. ICP Filing Number:
Internet drug information service qualification certificate number:（藏） Non-Commercial - 2018-0004 SEO